These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37187470)

  • 21. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia.
    Silitonga P; Jiang W; Wyatt S; Burhan E; Kes EFM; Long Q
    Trop Med Int Health; 2023 Jan; 28(1):43-52. PubMed ID: 36477995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and associated risk factors of drug-resistant tuberculosis in Thailand: results from the fifth national anti-tuberculosis drug resistance survey.
    Kamolwat P; Nateniyom S; Chaiprasert A; Disratthakit A; Mahasirimongkol S; Yamada N; Smithtikarn S
    Trop Med Int Health; 2021 Jan; 26(1):45-53. PubMed ID: 32997863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study.
    Cox H; Goig GA; Salaam-Dreyer Z; Dippenaar A; Reuter A; Mohr-Holland E; Daniels J; Cudahy PGT; Nicol MP; Borrell S; Reinhard M; Doetsch A; Beisel C; Gagneux S; Warren RM; Furin J
    J Clin Microbiol; 2022 Mar; 60(3):e0236221. PubMed ID: 35170980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
    Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B
    BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Tilahun M; Shimelis E; Wogayehu T; Assefa G; Wondimagegn G; Mekonnen A; Hailu T; Bobosha K; Aseffa A
    PLoS One; 2020; 15(8):e0236054. PubMed ID: 32750053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.
    Kurbatova EV; Cavanaugh JS; Shah NS; Wright A; Kim H; Metchock B; Van Deun A; Barrera L; Boulahbal F; Richter E; Martín-Casabona N; Arias F; Zemanova I; Drobniewski F; Santos Silva A; Coulter C; Lumb R; Cegielski JP
    Int J Tuberc Lung Dis; 2012; 16(3):355-7. PubMed ID: 22640449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia.
    Adane K; Ameni G; Bekele S; Abebe M; Aseffa A
    BMC Public Health; 2015 Jun; 15():572. PubMed ID: 26092570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis after introduction of the Hain
    Timire C; Sandy C; Kumar AMV; Ngwenya M; Murwira B; Takarinda KC; Harries AD
    Int J Infect Dis; 2019 Apr; 81():236-243. PubMed ID: 30776546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia.
    Mekonnen F; Tessema B; Moges F; Gelaw A; Eshetie S; Kumera G
    BMC Infect Dis; 2015 Oct; 15():461. PubMed ID: 26503269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Nyandoro G; Sandy C; Nkomo T; Mutero-Munyati S; Mharakurwa S; Chikaka E; Ngwenya M; Ndongwe G; Pepukai VM
    Pan Afr Med J; 2021; 39():128. PubMed ID: 34527144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis.
    Tabriz NS; Skak K; Kassayeva LT; Omarkulov BK; Grigolashvili MA
    Microb Drug Resist; 2020 Aug; 26(8):997-1004. PubMed ID: 32181685
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting.
    Chiang TY; Fan SY; Jou R
    PLoS One; 2018; 13(7):e0200755. PubMed ID: 30011319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and genetic determinant of drug-resistant tuberculosis among patients completing intensive phase of treatment in a Tertiary Referral Center in Nigeria.
    Mohammad AB; Iliyasu G; Habib AG
    Int J Mycobacteriol; 2017; 6(1):47-51. PubMed ID: 28317805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014-2018.
    Bahizi G; Majwala RK; Kisaka S; Nyombi A; Musisi K; Kwesiga B; Bulage L; Ario AR; Turyahabwe S
    Antimicrob Resist Infect Control; 2021 May; 10(1):76. PubMed ID: 33964986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.